PASADENA, Calif.—Pasadena Bio Collaborative Incubator (PBC), a high tech incubator for early stage start-ups and a regional workforce development magnet for scientists seeking wet lab competency, announced the election of Erika A. Endrijonas, Ph.D., the current Superintendent/President of Pasadena City College to its Board of Directors.  “We are very pleased to have Dr. Endrijonas on our team and believe she will provide wise counsel to the board and to management”, said PBC Chairman and former Pasadena mayor Bill Bogaard. Bud Bishop, PBC President, remarked “We are grateful that she has accepted this responsibility and believe she will be a valuable contributor to our future. Very importantly, she will strengthen our relationship with Pasadena City College.” Dr. Endrijonas has a strong ...
Read More
The long road to building Pasadena into a biotech hub started with an academics predisposition and a brick building on Foothill Boulevard The Pasadena Bio Collaborative Incubator was the first such facility in Los Angeles. It has grown and now is internationally known. Healthcare and biotech companies are taking hold in Pasadena as the city doubles down on its educational and workforce assets to boost economic development. With Caltech and Pasadena City College, there are local science resources and the City of Pasadena and County of Los Angeles want to develop economic growth. But history shows most innovation starts off small, and with nurturing and investment, can yield tremendous results. The Pasadena Bio Collaborative Incubator has been an essential component ...
Read More
On May 31, 2019, the tenants participated in portable fire extinguisher training. They learned the A-B-Cs of portable fire extinguishers and had an opportunity to extinguish actual fires under controlled conditions ...
Read More
PASADENA, Calif.--(BUSINESS WIRE)-- Privately held InvVax, Inc. (Pasadena, CA), in collaboration with Trudeau Institute Contract Research Organization and Hong Kong University, announced that it has demonstrated preclinical success for its universal flu vaccine candidate. Arguably the most formidable characteristic of the influenza virus is its ability to rapidly mutate, owing to a high error rate of the enzymes which make copies of its genome. This leads to the generation of hundreds of circulating strains, and the constant shifting of those strains. Each year the World Health Organization predicts the most dominant circulating strains for inclusion in the next annual flu vaccine, but often those predictions are erroneous, causing the ineffectiveness of the vaccine. The constant genetic movement of the virus ...
Read More
Skingenix, USA has joined the Pasadena Bio Collaborative Incubator. Skingenix, USA specializes in the research and development of multi-compound products for dermal regeneration. As an innovative and mission-driven company, Skingenix pursues a standard of excellence in the regenerative medical industry with an emphasis on developing organ in situ regenerative products for improving human health and quality of life. The Company has completed a Phase II randomized and controlled multi-center clinical study to assess the safety and efficacy of their investigational product in patients with Diabetic Foot Ulcers in the USA and currently engaged in further development of their investigational product (MW-III) ...
Read More
Loading...